224 related articles for article (PubMed ID: 26936516)
21. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
[TBL] [Abstract][Full Text] [Related]
22. Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors.
Kim M; Lee C; Hong J; Kim J; Jeong JY; Park NJ; Kim JE; Park JY
Cancer Res Treat; 2023 Apr; 55(2):429-441. PubMed ID: 36470260
[TBL] [Abstract][Full Text] [Related]
23. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
Hamblin A; Wordsworth S; Fermont JM; Page S; Kaur K; Camps C; Kaisaki P; Gupta A; Talbot D; Middleton M; Henderson S; Cutts A; Vavoulis DV; Housby N; Tomlinson I; Taylor JC; Schuh A
PLoS Med; 2017 Feb; 14(2):e1002230. PubMed ID: 28196074
[TBL] [Abstract][Full Text] [Related]
24. Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.
Zazo S; Pérez-Buira S; Carvajal N; Plaza-Sánchez J; Manso R; Pérez-González N; Dominguez C; Prieto-Potin I; Rubio J; Dómine M; Lozano V; Mohedano P; Carcedo D; Carias R; Rojo F
Cancer Med; 2024 Feb; 13(3):e6827. PubMed ID: 38213074
[TBL] [Abstract][Full Text] [Related]
25. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
27. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
28. Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue.
Fassunke J; Haller F; Hebele S; Moskalev EA; Penzel R; Pfarr N; Merkelbach-Bruse S; Endris V
Int J Mol Med; 2015 Nov; 36(5):1233-43. PubMed ID: 26352389
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel mutations in FFPE lung adenocarcinomas using DEPArray sorting technology and next-generation sequencing.
Lee JW; Shin JY; Seo JS
J Appl Genet; 2018 Aug; 59(3):269-277. PubMed ID: 29525983
[TBL] [Abstract][Full Text] [Related]
30. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
[TBL] [Abstract][Full Text] [Related]
31. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
[TBL] [Abstract][Full Text] [Related]
32. Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology.
Qiu T; Guo H; Zhao H; Wang L; Zhang Z
Sci Rep; 2015 Jun; 5():11317. PubMed ID: 26066407
[TBL] [Abstract][Full Text] [Related]
33. A newly developed capture-based sequencing panel for genomic assay of lung cancer.
Im SW; Chae J; Jang SS; Choi J; Yun J; Cha S; Kwon NJ; Jeon YK; Hwang Y; Kim M; Kim TM; Kim DW; Kim JI; Kim YT
Genes Genomics; 2020 Jul; 42(7):751-759. PubMed ID: 32449066
[TBL] [Abstract][Full Text] [Related]
34. Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing.
Zhong Q; Wagner U; Kurt H; Molinari F; Cathomas G; Komminoth P; Barman-Aksözen J; Schneider-Yin X; Rey JP; Vassella E; Rogel U; Diebold J; McKee T; Jochum W; Kashofer K; Hofman P; Zischka M; Moch H; Rechsteiner M; Wild PJ
Pathol Res Pract; 2018 Jul; 214(7):957-963. PubMed ID: 29807778
[TBL] [Abstract][Full Text] [Related]
35. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
Lee SH; Lee B; Shim JH; Lee KW; Yun JW; Kim SY; Kim TY; Kim YH; Ko YH; Chung HC; Yu CS; Lee J; Rha SY; Kim TW; Jung KH; Im SA; Moon HG; Cho S; Kang JH; Kim J; Kim SK; Ryu HS; Ha SY; Kim JI; Chung YJ; Kim C; Kim HL; Park WY; Noh DY; Park K
Cancer Res Treat; 2019 Jan; 51(1):211-222. PubMed ID: 29690749
[TBL] [Abstract][Full Text] [Related]
36. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
Deeb KK; Hohman CM; Risch NF; Metzger DJ; Starostik P
Arch Pathol Lab Med; 2015 Jul; 139(7):913-21. PubMed ID: 26125431
[TBL] [Abstract][Full Text] [Related]
37. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F
Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599
[TBL] [Abstract][Full Text] [Related]
38. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
39. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
40. Performance comparison of NextSeq and Ion Proton platforms for molecular diagnosis of clinical oncology.
Cao F; Gao L; Wei L; Chen Z; Wang Y; Ran X; Meng X; Tao J
Tumori; 2017 May; 103(3):223-230. PubMed ID: 28127742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
